Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cantargia AB's Enterprise Value is kr729.17 Mil.
Cantargia AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-240.76 Mil. Therefore, Cantargia AB's EV-to-EBIT ratio for today is -3.03.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Cantargia AB's Enterprise Value is kr729.17 Mil.
Cantargia AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-237.31 Mil. Therefore, Cantargia AB's EV-to-EBITDA ratio for today is -3.07.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Cantargia AB's Enterprise Value is kr729.17 Mil.
Cantargia AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.00 Mil. Therefore, Cantargia AB's EV-to-Revenue ratio for today is .
Cantargia AB Enterprise Value Historical Data
The historical data trend for Cantargia AB's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cantargia AB's Enterprise Value
For the Biotechnology subindustry, Cantargia AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantargia AB's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantargia AB's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Cantargia AB's Enterprise Value falls into.
Cantargia AB Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Cantargia AB's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantargia AB (OSTO:CANTA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Cantargia AB's current Enterprise Value is kr729.17 Mil.
Cantargia AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-240.76 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Cantargia AB's current Enterprise Value is kr729.17 Mil.
Cantargia AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-237.31 Mil.
Cantargia AB's current Enterprise Value is kr729.17 Mil.
Cantargia AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantargia AB Enterprise Value Related Terms
Thank you for viewing the detailed overview of Cantargia AB's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:CANTA has been successfully added to your 